Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 33

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

RNAi-based modulation of IFN-γ signaling in skin

Tang, Qi, Sousa, Jacquelyn, Echeverria, Dimas, Fan, Xueli, Hsueh, Ying-Chao, Afshari, Khashayar, MeHugh, Nicholas, Cooper, David A., Vangjeli, Lorenc, Monopoli, Kathryn, Okamura, Ken, Biscans, Annabelle, Clauss, Adam, Harris, John E., Khvorova, Anastasia·2022·Molecular Therapy

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2022.04.019

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 46

  1. Ruffilli, 2019, MIG in cutaneous systemic lupus erythematosus, Clin. Ter, 170, e71
  2. Rork, 2016, Understanding autoimmunity of vitiligo and alopecia areata, Curr. Opin. Pediatr., 28, 463, 10.1097/MOP.0000000000000375 · DOI
  3. Harris, 2012, A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin, J. Invest. Dermatol., 132, 1869, 10.1038/jid.2011.463 · DOI · Paper page
  4. Shao, 2019, IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus, Sci. Transl. Med., 11, eaav7561, 10.1126/scitranslmed.aav7561 · DOI · Paper page
  5. Rashighi, 2014, CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, Sci. Transl. Med., 6, 223ra23, 10.1126/scitranslmed.3007811 · DOI · Paper page
  6. Richmond, 2017, Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease, J. Invest. Dermatol., 137, 350, 10.1016/j.jid.2016.09.016 · DOI · Paper page
  7. Richmond, 2017, CXCR3 depleting antibodies prevent and reverse vitiligo in mice, J. Invest. Dermatol., 137, 982, 10.1016/j.jid.2016.10.048 · DOI · Paper page
  8. van den Boorn, 2009, Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients, J. Invest. Dermatol., 129, 2220, 10.1038/jid.2009.32 · DOI · Paper page
  9. Xing, 2014, Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition, Nat. Med., 20, 1043, 10.1038/nm.3645 · DOI · Paper page
  10. Kennedy Crispin, 2016, Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata, JCI Insight, 1, e89776, 10.1172/jci.insight.89776 · DOI · Paper page
  11. King, 2022, Two phase 3 trials of Baricitinib for alopecia areata, N. Engl. J. Med., 386, 1687, 10.1056/NEJMoa2110343 · DOI · Paper page
  12. Rothstein, 2017, Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib, J. Am. Acad. Dermatol., 76, 1054, 10.1016/j.jaad.2017.02.049 · DOI · Paper page
  13. Rosmarin, 2020, Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial, Lancet, 396, 110, 10.1016/S0140-6736(20)30609-7 · DOI · Paper page
  14. Schwartz, 2017, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Nat. Rev. Drug Discov., 16, 843, 10.1038/nrd.2017.201 · DOI · Paper page
  15. Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888 · DOI · Paper page
  16. Khvorova, 2017, The chemical evolution of oligonucleotide therapies of clinical utility, Nat. Biotechnol., 35, 238, 10.1038/nbt.3765 · DOI · Paper page
  17. Scott, 2020, Givosiran: first approval, Drugs, 80, 335, 10.1007/s40265-020-01269-0 · DOI · Paper page
  18. Scott, 2021, Lumasiran: first approval, Drugs, 81, 277, 10.1007/s40265-020-01463-0 · DOI · Paper page
  19. Lamb, 2021, Inclisiran: first approval, Drugs, 81, 389, 10.1007/s40265-021-01473-6 · DOI · Paper page
  20. Biscans, 2019, Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo, Nucleic Acids Res., 47, 1082, 10.1093/nar/gky1239 · DOI · Paper page
  21. Biscans, 2019, The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo, J. Control Release, 302, 116, 10.1016/j.jconrel.2019.03.028 · DOI
  22. Biscans, 2021, Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles, Mol. Ther., 29, 1382, 10.1016/j.ymthe.2020.12.023 · DOI
  23. Birmingham, 2007, A protocol for designing siRNAs with high functionality and specificity, Nat. Protoc., 2, 2068, 10.1038/nprot.2007.278 · DOI · Paper page
  24. Shmushkovich, 2018, Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs, Nucleic Acids Res., 46, 10905, 10.1093/nar/gky745 · DOI
  25. Hassler, 2018, Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo, Nucleic Acids Res., 46, 2185, 10.1093/nar/gky037 · DOI · Paper page
  26. Moran, 2012, Incyte comes of age with JAK inhibitor approval, Nat. Biotechnol., 30, 3, 10.1038/nbt0112-3 · doi:10.1038/nbt0112-3
  27. Roberts, 2020, Advances in oligonucleotide drug delivery, Nat. Rev. Drug Discov., 19, 673, 10.1038/s41573-020-0075-7 · DOI · Paper page
  28. Valente, 1992, Distribution of interferon-gamma receptor in human tissues, Eur. J. Immunol., 22, 2403, 10.1002/eji.1830220933 · DOI · Paper page
  29. Hu, 2009, Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases, Immunity, 31, 539, 10.1016/j.immuni.2009.09.002 · DOI · Paper page
  30. Ivashkiv, 2018, IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy, Nat. Rev. Immunol., 18, 545, 10.1038/s41577-018-0029-z · DOI · Paper page
  31. Seung, 2011, Inhibiting CXCR3-dependent CD8+ T cell trafficking enhances tolerance induction in a mouse model of lung rejection, J. Immunol., 186, 6830, 10.4049/jimmunol.1001049 · DOI
  32. Groom, 2012, CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation, Immunity, 37, 1091, 10.1016/j.immuni.2012.08.016 · DOI · Paper page
  33. Ledford, 2018, Gene-silencing technology gets first drug approval after 20-year wait, Nature, 560, 291, 10.1038/d41586-018-05867-7 · DOI · Paper page
  34. Maouia, 2017, Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients, Pigment Cell Melanoma Res, 30, 259, 10.1111/pcmr.12559 · DOI
  35. Ferguson, 2020, Cell type impacts accessibility of mRNA to silencing by RNA interference, Mol. Ther. Nucleic Acids, 21, 384, 10.1016/j.omtn.2020.06.006 · DOI
  36. Małecka, 2020, Ribosomes clear the way for siRNA targeting, Nat. Struct. Mol. Biol., 27, 775, 10.1038/s41594-020-0495-4 · DOI
  37. Jouanguy, 1997, Infections in IFNGR-1-deficient children, J. Interferon Cytokine Res., 17, 583, 10.1089/jir.1997.17.583 · DOI
  38. Jouanguy, 1999, A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection, Nat. Genet., 21, 370, 10.1038/7701 · DOI · Paper page
  39. van de Vosse, 2017, IFN-γR1 defects: mutation update and description of the IFNGR1 variation database: van de VOSSE and van DISSEL, Hum. Mutat., 38, 1286, 10.1002/humu.23302 · DOI
  40. Horras, 2011, Regulation of hepatocyte fate by interferon-γ, Cytokine Growth Factor Rev., 22, 35, 10.1016/j.cytogfr.2011.01.001 · DOI
  41. Mohammadi, 2021, CC and CXC chemokines play key roles in the development of polyomaviruses related pathological conditions, Virol. J., 18, 111, 10.1186/s12985-021-01582-4 · DOI
  42. Prausnitz, 2017, Engineering microneedle patches for vaccination and drug delivery to skin, Annu. Rev. Chem. Biomol. Eng., 8, 177, 10.1146/annurev-chembioeng-060816-101514 · DOI · Paper page
  43. Tadros, 2020, STAR particles for enhanced topical drug and vaccine delivery, Nat. Med., 26, 341, 10.1038/s41591-020-0787-6 · DOI
  44. Dharamdasani, 2020, Topical delivery of siRNA into skin using ionic liquids, J. Control Release, 323, 475, 10.1016/j.jconrel.2020.04.038 · DOI
  45. Mandal, 2020, Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations, Sci. Adv., 6, eabb6049, 10.1126/sciadv.abb6049 · DOI
  46. Turanov, 2018, RNAi modulation of placental sFLT1 for the treatment of preeclampsia, Nat. Biotechnol., 36, 1164, 10.1038/nbt.4297 · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D. A., Vangjeli, L., Monopoli, K., Okamura, K., Biscans, A., Clauss, A., Harris, J. E., & Khvorova, A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2022-08
Volume
30
Issue
8
Pages
2709-2721
ISSN
1525-0016
Cited by
33
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RNAi-based modulation of IFN-γ signaling in skin. https://app.cochat.ai/papers/10.1016/j.ymthe.2022.04.019
The paper
Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D. A., Vangjeli, L., Monopoli, K., Okamura, K., Biscans, A., Clauss, A., Harris, J. E., & Khvorova, A. (2022). RNAi-based modulation of IFN-γ signaling in skin. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2022.04.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.